Bilateral adrenal neuroblastoma: clinical presentation, diagnostic and therapeutic approaches, treatment results

Bilateral adrenal neuroblastoma (BANB) is a very rare entity. It is more common in young children and has certain clinical features. Patients with BANB have a more favorable prognosis than patients with unilateral adrenal neuroblastoma (NB). The article presents an analysis of 29 cases of BANB in children who underwent treatment at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. This study is supported by the Independent Ethics Committee and approved by the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The analysis was performed for the period from April 2012 to December 2018. Bilateral adrenal involvement was diagnosed on the basis of analysis/assessment of the results of all relevant imaging and instrumental tests. Additionally, we performed a retrospective analysis of the findings of computed tomography, magnetic resonance imagining, and scintigraphy with ¹²³I-metaiodobenzylguanidine (¹²³I-MIBG). In view of ¹²³I-MIBG scintigraphy sensitivity threshold, and in order to confirm the diagnosis, imaging findings were reviewed by an experienced radiologist. The patients received therapy in accordance with the risk-adapted NB-2004 protocol. Here, we analyzed the details of clinical presentation of the disease, age at the time of diagnosis, time from the disease onset to diagnosis, the presence or absence of life-threatening symptoms (LTS) and adrenal insufficiency, the aspects of patient management (including special aspects of surgical treatment), and treatment results. The median age at the time of diagnosis was 1.9 months. The patients were divided into 3 groups: children with localized BANB; children with true stage 4 disease; children with stage 4S disease. Most patients had metastatic NB, whereby stage 4S cases prevailed (55%, n = 16). Given the low sensitivity of MIBG scintigraphy for the detection of small tumours (less than 2 cm), one should use a comprehensive approach to the assessment of the results of imaging and instrumental tests in patients with BANB in order to confirm bilateral involvement. At diagnosis, about half of the patients with BANB (48%) had clinical symptoms associated with the presence of a retroperitoneal tumour mass and massive hepatomegaly because of liver metastases. Thirty-four percent of patients developed LTS. One of the typical features of BANB was the frequent development of adrenal insufficiency (in 41% of cases) caused by bilateral adrenal involvement, and this should be taken into account when performing diagnostic investigations and providing treatment to patients. Since bilateral radical resection is associated with the inevitable development of adrenal insufficiency, surgical treatment should be determined on an individual basis. Bilateral adrenalectomy is not generally recommended and can be undertaken after an interdisciplinary discussion in case of unfavourable course of the disease (e.g. in case of recurrence). Even if patients with BANB develop certain complications or events (progression) their prognosis is still good. The three- and five-year event-free survival rates in patients with BANB were 86 ± 6.4%. The three- and five-year overall survival rates were 100%. The analysis of patients with BANB showed that they have a more favourable course of the disease, and this may serve as grounds for assigning such patients into a special group. In view of the degree of tumour extension, the specifics of staging, and frequent development of adrenal insufficiency, standard check-ups should be complemented by endocrine monitoring, and surgical approaches should be chosen on an individual basis.

1. Park J.R., Bagatell R., London W.B., Maris J.M., Cohn S.L., Mattay K.K., Hogarty M.; COG Neuroblastoma Committee. Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 2013; 60 (6): 985–93. DOI: 10.1002/pbc.24433

2. Evans A. Neuroblastoma: A historical perspective 1864–1998. In: Brodeur G.M., Sawada T., Tsuchida Y., Voûte P.A., eds. Neuroblastoma. Elsevier Science; Amsterdam; 2000. Рp. 1–7

3. Heck J.E., Ritz B., Hung R.J., Hashibe M., Boffetta P. The epidemiology of neuroblastoma: a review. Paediatr Perinatal Epidemiol 2009; 23 (2): 125–43. DOI: 10.1111/j.1365-3016.2008.00983.x

4. Vo K.T., Matthay K.K., Neuhaus J., London W.B., Hero B., Ambros P.F., et al. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol 2014; 32 (28): 3169– 76. DOI: 10.1200/JCO.2014.56.1621

5. Pagès P.M., Dufour C., Fasola S., Michon J., Boutard P., Gentet J.C., Hartmann O. Bilateral adrenal neuroblastoma. Pediatr Blood Cancer 2009; 52 (2): 196–202. DOI: 10.1002/pbc.21765

6. Johnston D.L., Sweeney B., Halton J.M. Bilateral adrenal neuroblastoma: stage V disease. J Pediatr Hematol Oncol 2007; 29 (9): 652–5. DOI: 10.1097/MPH.0b013e318142b788

7. Lo Cunsolo C., Casciano I., Gambini C., De Bernardi B., Tonini G.P., Romani M. Molecular alterations in a case of bilateral adrenal neuroblastoma. Med Pediatr Oncol 2001; 36 (4): 491–3. DOI: 10.1002/mpo.1115

8. Dinh T., Truong B., Matthay K.K., DuBois S.G. Comparison of Clinical Features and Outcomes in Patients with Bilateral Versus Unilateral Adrenal Neuroblastoma. J Pediatr Hematol Oncol 2017; 39 (2): 108–13. DOI: 10.1097/MPH.0000000000000692

9. Kramer S.A., Bradford W.D., Anderson E.E. Bilateral adrenal neuroblastoma. Cancer 1980; 45 (8): 2208-2212. DOI: 10.1002/1097-0142(19800415)45:8<2208::aid-cncr2820450833>3.0.co;2-a

10. Shaw A., Sabio H. Bilateral adrenal neuroblastoma. Am J Pediatr Hematol Oncol 1984; 6: 41–3.

11. Brodeur G.M., Pritchard J., Berthold F., Carlsen N.L., Castel V., Castelberry R.P., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11 (8): 1466–77. DOI: 10.1200/jco.1993.11.8.1466

12. NB2004 Trial Protocol for Risk Adapted Treatment of Children with Neuroblastoma Berthold F. (principal investigator) [Электронный ресурс]. URL: http://www.kinderkrebsinfo.de/dlja_specialistov/protokoly_gpoh/pohkinderkrebsinfotherapiestudien/nb2004/index_rus.html (Дата обращения 27.01.2020).

13. Kaplan E.L., Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc 1958; 282 (53): 457–81. DOI: 10.1080/01621459.1958.10501452

14. Ninane J. Prognostic factors in neuroblastoma: a new one. Pediatr Hematol Oncol 1992; 9 (1): 5–7. DOI: 10.3109/08880019209006388

15. Nickerson H.J., Matthay K.K., Seeger R.C., Brodeur G.M., Shimada H., Perez C., et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 2000; 18 (3): 477–86. DOI: 10.1200/JCO.2000.18.3.477

16. Trochet D., Bourdeaut F., Janoueix-Lerosey I., Deville A., de Pontual L., Schleiermacher G., et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 2004; 74 (4): 761–4. DOI: 10.1086/383253

17. Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455 (7215): 930–5. DOI: 10.1038/nature07261

18. Perri P., Bachetti T., Longo L., Matera I., Seri M., Tonini G.P., Ceccherini I. PHOX2B mutations and genetic predisposition to neuroblastoma. Oncogene 2005; 24 (18): 3050–3. DOI: 10.1038/sj.onc.1208532

19. Bourdeaut F., Ferrand S., Brugières L., Hilbert M., Ribeiro A., Lacroix L., et al.; Comité Neuroblastome of the Société Francaise de Cancérologie. ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. Eur J Hum Genet 2012; 20 (3): 291–7. DOI: 10.1038/ejhg.2011. 195

20. Fassnacht M., Arlt W., Bancos I., Dralle H., Newell-Price J., Sahdev A., et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175 (2): G1–34. DOI: 10.1530/eje-16-0467

21. Husebye E.S., Allolio B., Arlt W., Badenhoop K., Bensing S., Betterle C., et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med 2014; 275 (2): 104–15. DOI: 10.1111/joim.12162

22. Бельцевич Д.Г., Кузнецов Н.С., Солдатова Т.В., Ванушко В.Э. Инциденталома надпочечников. Эндокринная хирургия 2009: 3 (1): 19–23. DOI: 10.14341/2306-3513-2009-1-19-23

23. Nieman L.K., Biller B.M., Findling J.W., Newell-Price J., Savage M.O., Stewart P.M., Montori V.M. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93 (5): 1526–40. DOI: 10.1210/jc.2008-0125

24. Nieman L.K., Biller B.M., Findling J.W., Murad M.H., Newell-Price J., Savage M.O., Tabarin A.; Endocrine Society. Treatment of Cushing's syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100 (8): 2807–31. DOI: 10.1210/jc.2015-1818

25. Jamila E., Mohamed O., Mohamed S., Mhamed H. Unusual Evolution of Bilateral Neuroblastoma. J Cancer Oncol 2018; 2 (3): 000128

26. Heyman S., Evans A.E., D'Angio G.J. I-131 metaiodobenzylguanidine: diagnostic use in neuroblastoma patients in relapse. Med Pediatr Oncol 1988; 16 (5): 337–40. DOI: 10.1002/mpo.2950160509

27. Schmiegelow K., Siimes M.A., Agertoft L., Berglund G., Storm-Mathisen I., Andreassen M., et al. Radioiodobenzylguanidine scintigraphy of neuroblastoma: conflicting results, when compared with standard investigations. Med Pediatr Oncol 1989; 17 (2): 126–30. DOI: 10.1002/mpo.2950170210

28. Brouard J., Nivot S., Deschrevel G., Duhamel J.F. Neonatal Pepper’s syndrome with bilateral adrenal tumor. Arch Fr Pediatr 1990; 47 (7): 543.

29. Hero B., Simon T., Spitz R., Ernestus K., Gnekow A.K., Scheel-Walter H.G., et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 2008; 26 (9): 1504–10. DOI: 10.1200/JCO.2007.12.3349

30. Castel V., Tovar J.A., Costa E., Cuadros J., Ruiz A., Rollan V., et al. The role of surgery in stage IV neuroblastoma. J Pediatr Surg 2002; 37 (11): 1574–8. DOI: 10.1053/jpsu.2002.36187